Donald S. Coffey to receive Margaret Foti Award at AACR Annual Meeting 2015

NewsGuard 100/100 Score

Donald S. Coffey, PhD, will be honored with the ninth annual American Association for Cancer Research (AACR) Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22. He will receive the award during the opening ceremony, Sunday, April 19, 8:15 a.m. ET, in Hall A of the Pennsylvania Convention Center.

Coffey, a fellow of the AACR Academy, and the Catherine Iola and J. Smith Michael distinguished professor of urology at Johns Hopkins School of Medicine in Baltimore, is being honored for his tremendous leadership and profound contributions to cancer research. His distinct reputation as a natural advocate and leader is evidenced by his extraordinary tenure as AACR president (1997-1998), which resulted in a number of new exciting initiatives for the organization. Likewise, his pioneering work on the structure of the cell nuclei and the pathogenesis of prostate cancer, coupled with his dedication to mentoring young cancer researchers and promoting cancer research nationally, epitomizes the spirit of this award.

"Dr. Coffey is an internationally recognized research scientist who has made seminal contributions to numerous areas of cancer research," said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. "His work on the nuclear matrix established a new paradigm for understanding the biology of normal and cancer cells, while his prostate cancer research helped change the face of that deadly disease. However, Dr. Coffey's impact on cancer research extends far beyond his scientific achievements. His outstanding leadership skills, dedication to mentoring young investigators, passionate advocacy for sustained increases in funding for cancer research, and remarkable ability to translate complex scientific concepts into lay language make him an icon in the field and a true champion of cancer research. He is greatly deserving of this award."

The Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research, established in 2007, recognizes an individual whose leadership and extraordinary achievements in cancer research, or in support of cancer research, have made a major impact on the field.

"To receive this premier award honoring Dr. Margaret Foti, who has built the American Association for Cancer Research into the world's leading organization to impact the control of cancer, fulfills my lifetime dream. Sixty years ago, my wife Eula and I accepted our joint calling to serve this mission. Johns Hopkins University, the AACR, and hundreds of colleagues, supported by private and public donors, have all made this possible. We thank all of you," said Coffey.

Coffey has made many important discoveries about abnormal and normal cell behavior and has launched major new research avenues in cell biology; he is widely known for his discovery of the nuclear matrix and the fact that DNA synthesis occurs on this matrix. He characterized the first Dunning animal models, which are used to isolate tumor metastasis genes and design chemotherapy regimens in prostate cancer. Coffey was the first to establish methods to identify androgen-insensitive prostate tumors and to elucidate the mechanisms of clonal selection in this insensitivity. He has also done groundbreaking work on telomerase in prostate cancer and contributed to the first prostate cancer gene therapy trial ever conducted.

Coffey's outstanding service to the AACR began in 1976. In addition to his tenure as president from 1997 to 1998, he has been a member of the AACR board of directors (1993-1996) and Nominating Committee (2001-2003), co-chair of the Science Education Committee, program chair of the AACR Annual Meeting 1995, and a member of the Public Education Committee and Long-range Planning Committee, as well as associate editor of Cancer Research. He has also provided his mentorship in the Scientist?Survivor Program and for early-career scientists.

Coffey has served in various other leadership positions throughout his career, including the National Cancer Advisory Board, the board of directors of the National Coalition for Cancer Research, president of the Society for Basic Urological Research, national chair of the National Cancer Institute's National Prostatic Cancer Program, and director of the Brady Laboratory for Reproductive Biology and the research laboratories in the Department of Urology at Johns Hopkins.

Coffey has been recognized with numerous other honors, including the St. Paul's Medal from the British Association of Urological Surgeons, the Achievement Award from the American Urological Association, the First Yamanouchi Award from the Society of International Urology, the Eugene Fuller Prostate Award from the American Urological Society, and the Falk Award from the National Institute of Environmental Science.

While working toward his bachelor's degree in chemistry from East Tennessee State University, which he received in 1957, Coffey was a chemist at the North American Rayon Corporation. Upon graduating, Coffey spent two years as a chemical engineer at the Westinghouse Corporation in Baltimore. He began his tenure at Johns Hopkins in 1959, where he has served since, joining the Johns Hopkins Hospital as acting director of the Brady Urological Research Laboratory. He also received his doctorate from the university's medical school in 1964. Additionally, he is currently an adjunct professor of medicine at Howard University in Washington, D.C.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Non-invasive detection and treatment of ovarian cancer with new radiotheranostic system